Fundraising Fox

Elkedonia

3 known investors

Elkedonia is developing a novel antidepressant aimed at patients who do not respond to current depression treatments, using a precision medicine approach. It focuses on mental health disorders and antidepressant therapy.

BiotechDigital HealthMental Health

Investors · 3

Angelini VenturesRome
CARMA FUNDMunich
Kurma PartnersParis · $162K – $10.8M

Funding

SEC filings, press & company announcements
  • Undisclosed amountSeed RoundJul 2025
    Source ↗
  • Undisclosed amountSeed RoundJun 2025 · 3 sources
    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Elkedonia Secures $12.58M Seed Round to Transform Precision Therapeutics - Fenoms Talentfenomstalent.com · Jul 2025Neuroplastogens: the growing field of safer psychedelic alternativeslabiotech.eu · Jun 2025Elkedonia Secures €11M to Develop Neuropsychiatric Therapeuticsclinicaltrialvanguard.com · Jun 2025Elkedonia Closes EUR 11M in Seed Fundingfinsmes.com · Jun 2025Elkedonia closes EUR 11 million seed round to advance neuroplastogens as novel therapeutics for depression and neuropsychiatric disorders - BioSpacebiospace.com · Jun 2025Elkedonia Raises €11.25M Seed Round to Advance Neuroplastogen Therapy for Depressionpharmtech.com · Jun 2025

Frequently asked questions

What does Elkedonia do?
Elkedonia is developing a novel antidepressant aimed at patients who do not respond to current depression treatments, using a precision medicine approach. It focuses on mental health disorders and antidepressant therapy.
Who are Elkedonia's investors?
Elkedonia's investors include Angelini Ventures, CARMA FUND, Kurma Partners.